Profile
| Metric | Value |
|---|---|
| Full Name | Summit Therapeutics Inc. |
| Ticker | NASDAQ: SMMT |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | smmttx.com |
| Employees | 159 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $17.65 | |
| Price, 1D Change | +5.00% | |
| Market Cap | $13B | |
| - | ||
| PE Ratio | - | |
| Beta | 1.57 | |
| Revenue | $0 | |
| Revenue, 1Y Change | 0.00% | |
| EPS | -$0.31 | |
| EPS, 1Y Change | +68.96% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$0.31 | |
| EPS Estimate | -$0.77 | |
| EPS Est. Change | -148.93% | |
| Revenue | $0.00 | |
| Revenue Estimate | $57.43M | |
| Revenue Est. Change | - | |
| Current Price | $17.65 | |
| Price Target | - | $35.65 |
| Price Tgt. Change | - | +101.97% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$0.24 | -$0.31 | -28.44% | |
| -$0.77 | N/A | -148.93% | |
| -$0.75 | N/A | -142.27% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| - | $0.00 | - | |
| $57.43M | N/A | - | |
| $1.89M | N/A | - |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +6.01% | |
| Price, 3Y | +267.71% | |
| Market Cap, 1Y | +6.99% | |
| Market Cap, 3Y | +1,196.77% | |
| Revenue, 1Y | 0.00% | |
| Revenue, 3Y | -100.00% | |
| EPS, 1Y | +68.96% | |
| EPS, 3Y | +67.94% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $17.65 | |
| SMA 200 | $21.76 | |
| SMA 200 vs Price | +23.28% | |
| SMA 50 | $17.82 | |
| SMA 50 vs Price | +0.96% | |
| Beta | 1.57 | |
| ATR | $0.99 | |
| 14-Day RSI | 47.98 | |
| 10-Day Volatility | 88.56% | |
| 1-Year Volatility | 97.08% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $0.00 | |
| EPS | -$0.31 | |
| Gross Profit | -$89.00K | |
| Gross Margin | - | |
| Operating Profit | -$211.30M | |
| Operating Margin | - | |
| Net Income | -$221.32M | |
| Net Margin | - | |
| EBITDA | -$211.22M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.02 | |
| Current Ratio | 10.15 | |
| Quick Ratio | 10.15 | |
| - | ||
| F-Score | - | |
| Altman Z-Score | 163.96 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | - | |
| PB Ratio | 68.34 | |
| EV/EBITDA | -13.80 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $388.75M | |
| Cash & Equivalents | $412.67M | |
| Total Assets | $435.56M | |
| Current Assets | $423.75M | |
| Total Liabilities | $46.81M | |
| Current Liabilities | $41.73M | |
| Total Debt | $7.22M | |
| Short Term Debt | $3.77M | |
| Accounts Payable | $4.64M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $221.32M | |
| Operating Expenses | $211.22M | |
| Cost Of Goods Sold | $89.00K | |
| SG&A | $0.00 | |
| D&A | $89.00K | |
| Interest Expense | $0.00 | |
| Income Tax | -$313.00K |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$142.11M | |
| CFI | -$205.34M | |
| CFF | $381.23M | |
| Capex | $139.00K | |
| Free Cash Flow | -$142.25M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Barclays | → | |
| Wolfe Research | ||
| Guggenheim | → | |
| HC Wainwright & Co. | → | |
| Barclays | → | |
| JMP Securities | → | |
| Citigroup | → | |
| Barclays | ||
| HC Wainwright & Co. | → | |
| HC Wainwright & Co. | → |
Analyst sentiment
Institutional ownership
Screeners with SMMT
Data Sources & References
- SMMT Official Website www.smmttx.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1599298/000159929825000128/0001599298-25-000128-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1599298/000159929825000048/0001599298-25-000048-index.htm
- SMMT Profile on Yahoo Finance finance.yahoo.com/quote/SMMT
- SMMT Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/smmt
FAQ
What is the ticker symbol for Summit Therapeutics Inc.?
The ticker symbol for Summit Therapeutics Inc. is NASDAQ:SMMT
Does Summit Therapeutics Inc. pay dividends?
No, Summit Therapeutics Inc. does not pay dividends
What sector is Summit Therapeutics Inc. in?
Summit Therapeutics Inc. is in the Healthcare sector
What industry is Summit Therapeutics Inc. in?
Summit Therapeutics Inc. is in the Biotechnology industry
What country is Summit Therapeutics Inc. based in?
Summit Therapeutics Inc. is headquartered in United States
When did Summit Therapeutics Inc. go public?
Summit Therapeutics Inc. initial public offering (IPO) was on March 5, 2015
Is Summit Therapeutics Inc. in the S&P 500?
No, Summit Therapeutics Inc. is not included in the S&P 500 index
Is Summit Therapeutics Inc. in the NASDAQ 100?
No, Summit Therapeutics Inc. is not included in the NASDAQ 100 index
Is Summit Therapeutics Inc. in the Dow Jones?
No, Summit Therapeutics Inc. is not included in the Dow Jones index
When was Summit Therapeutics Inc. last earnings report?
Summit Therapeutics Inc.'s most recent earnings report was on October 20, 2025
When does Summit Therapeutics Inc. report earnings?
The next expected earnings date for Summit Therapeutics Inc. is February 24, 2026